Frontiers in aging neuroscience · 2026
Effects of transmembrane protein 106B genetic variations on disease progression in Parkinson's disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhao Wanbing, Liang Xiaoniu, Hu Bolin, Yu Wenbo, Wu Jianjun, Sun Yimin, Wang Jian, Fan Yun
Аннотация
BACKGROUND: Transmembrane protein 106B (TMEM106B) variations not only act as genetic modifiers of the risk of developing frontotemporal lobar degeneration but also correlate with the heterogeneity of clinicopathological phenotypes in other neurodegenerative diseases. However, the roles of TMEM106B in Parkinson's disease (PD) are sparsely explored. This study aims to explore whether TMEM106B variants influence the trajectories of clinical phenotypes in PD.
METHODS: We longitudinally followed 241 PD patients and genotyped their single nucleotide polymorphism (SNP) of rs3173615. Patients were categorized according to rs3173615 genotypes into GG (major allele homozygotes), GC (heterozygotes), and CC (minor allele homozygotes) groups. All patients completed clinical evaluations and neuropsychological tests at baseline and every follow-up. Linear mixed-effects models were adopted to evaluate the association between rs3173615 genotypes and longitudinal disease progression in PD.
RESULTS: At baseline, both the GG and GC groups presented less severe excessive daytime sleepiness than the CC group, and no association between the remaining clinical characteristics and the genotypes of rs3173615 was observed among the three groups. Longitudinally, compared with the CC group, the GC group manifested a significantly faster exacerbation of depression, visuospatial function and quality of life (QoL), and the GG group showed the same tendency as the GC group, though without statistical significance.
CONCLUSION: TMEM106B rs3173615 is a genetic modifier for the trajectory of depression, visuospatial function and QoL in PD. Our findings suggest the potential involvement of TMEM106B in the pathogenesis of disease progression in PD, especially in the deterioration of depression, cognition and QoL.
METHODS: We longitudinally followed 241 PD patients and genotyped their single nucleotide polymorphism (SNP) of rs3173615. Patients were categorized according to rs3173615 genotypes into GG (major allele homozygotes), GC (heterozygotes), and CC (minor allele homozygotes) groups. All patients completed clinical evaluations and neuropsychological tests at baseline and every follow-up. Linear mixed-effects models were adopted to evaluate the association between rs3173615 genotypes and longitudinal disease progression in PD.
RESULTS: At baseline, both the GG and GC groups presented less severe excessive daytime sleepiness than the CC group, and no association between the remaining clinical characteristics and the genotypes of rs3173615 was observed among the three groups. Longitudinally, compared with the CC group, the GC group manifested a significantly faster exacerbation of depression, visuospatial function and quality of life (QoL), and the GG group showed the same tendency as the GC group, though without statistical significance.
CONCLUSION: TMEM106B rs3173615 is a genetic modifier for the trajectory of depression, visuospatial function and QoL in PD. Our findings suggest the potential involvement of TMEM106B in the pathogenesis of disease progression in PD, especially in the deterioration of depression, cognition and QoL.